Sopharma AD (BUL:SFA)

Market Cap	1.39B
Revenue (ttm)	2.41B
Net Income (ttm)	102.39M
Shares Out	510.90M
EPS (ttm)	0.20
PE Ratio	13.33
Forward PE	n/a
Dividend	0.05 (1.90%)
Ex-Dividend Date	Jul 10, 2025

Volume	34,335
Average Volume	39,761
Open	2.730
Previous Close	2.740
Day's Range	2.660 - 2.730
52-Week Range	1.840 - 2.780
Beta	-0.13
RSI	54.33
Earnings Date	Oct 30, 2025

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices...

• Industry: Pharmaceutical Preparations
• Founded: 1933
• Employees: 5,599
• Stock Exchange: Bulgarian Stock Exchange
• Ticker Symbol: SFA

Financial Performance

In 2024, Sopharma AD's revenue was 2.14 billion, an increase of 13.27% compared to the previous year's 1.89 billion. Earnings were 77.85 million, a decrease of -18.89%.